Georgian biotech company to increase bacteriophage production capacity by 300% with EU, FAO $150,000 grant
The matching grant is a part of a total $1 million investment raised by the company aimed to allow for a 300% increase in PowerPhage’s production capacity. Photo: Biochimpharm.
Tweet 
Share
A Georgian company producing bacteriophages, Biochimpharm, has received a grant of $150,000 from the EU and FAO to support PowerPhage production, a natural, bacteriophage antimicrobial veterinary solution which reduces the use of antibiotics in meat production with a focus on poultry farms, announces the EU Delegation to Georgia.
????EU & @FAO support Biochimpharm, a Georgian biotech company known worldwide for producing bacteriophages – a sustainable alternative to antibiotics.
— EU Delegation Georgia ???????? (@EUinGeorgia) May 28, 2021
????https://t.co/a9bPyvID1S#EU4Georgia #EU4Business pic.twitter.com/2DDHLFWRJQ
The matching grant is a part of a total $1 million investment raised by the company aimed to allow for a 300% increase in PowerPhage’s production capacity.
The investment is mainly destined to upgrade the manufacturing line and to ensure EU good manufacturing practice compliance.
The widespread use of antibiotics in poultry farms increases health risks for consumers. Biochimpharm’s innovative products provide a Georgian-made alternative to veterinary antibiotics. With EU and FAO support, the company will be able to further develop its product, increase production and meet EU standards", said Dominik Papenheim, Team Leader for Economic Development and Market Opportunities at the Delegation of the EU to Georgia.
Biochimpharm has over 80 years of experience in research, development and the production of bacteriophages. The company is ISO 9001-2015 certified, holds 12 registered products and two international patents under its name.
The company currently exports its products to eight countries outside Georgia and is a legally authorised pharmaceutical manufacturer.